Prevest Denpro's 3D printer launch date shifted 19 months — and management didn't explain why
CEO said in May 2025 the printer was 'very soon' and not yet commercial; 13 months later he claimed sales began in November 2024, a contradiction that muddies the 162% growth figure.
What's new
- Q4FY26 revenue ₹18.94 cr, up 2.63% YoY; PAT ₹5.82 cr, up 13.23%.
- Full-year FY26 revenue ₹71.81 cr, up 13.9%; EBITDA margin 38.6%.
- 3D printer sales (Omni brand) grew 162% since claimed Nov 2024 launch.
- US market grew 37.58% via Accudent subsidiary and private label.
Themes from the call
Digital dentistry
Combined 3D printer and resin revenue surged ~40% YoY, billed as the primary growth engine despite the launch date confusion.
Capacity utilization
New digital dentistry, disinfectant and OraDoc lines running at only 18-20% capacity vs 68% for traditional products, offering a long runway but also execution risk.
Profitability
EBITDA margin stood at 40.87% in Q4 and 38.6% for the full year, supported by cost discipline even as top-line growth softened.
Guidance watch
- Indigenous 3D printer targeted for 2028; digital workflows expected to drive 40% of dental procedures within 5 years.
- Full facility capacity pegged at ~₹125 cr revenue – nearly double current run rate – but no timeline for reaching it.
Risk flags
- The 3D printer launch date flip-flop (Nov 2024 vs 'very soon' in May 2025) raises questions about management's narrative reliability.
- OraDoc segment declined 2% YoY due to MoCRA delays and Dubai disruptions; recovery depends on new products and online sales of unknown scale.
- Low utilization on new production lines (18-20%) means fixed-cost absorption is poor; profitability may come under pressure if volume growth does not materialize.
Key quotes
-
"We started selling 3D printers in November 2024."
— Dr. Sai Kalyan, CEO, Jun 2026 call -
"Very soon, we are launching it. Already sample pieces we have given in the market."
— Dr. Sai Kalyan, CEO, May 2025 call (prior)
The brief
Prevest Denpro has a growth story that works on paper. Digital dentistry revenue jumped ~40% in FY26, US private-label business surged 37.58%, and full-year revenue crossed ₹71 crore with margins at 38.6%. The Q4 numbers were soft (2.63% revenue growth), but the annual picture is one of consistent results in a tough global trade environment. The problem is the timeline for the product that is supposed to drive the next leg of growth.
In May 2025, CEO Dr. Sai Kalyan told investors the 3D printer was not yet commercial and that sample pieces were still in market testing. In the June 2026 call, he claimed the company started selling 3D printers in November 2024, 18 months before the current quarter and six months before the earlier 'very soon' statement. The 162% sales growth he cited uses that retroactive November 2024 base, not the one investors were led to expect.
That contradiction is more than a quibble about dates. It makes it hard to trust the growth narrative from the same management team. The underlying business has real strengths: 92-country export reach, new product pipelines (disinfectants, endodontic files), and headroom of about ₹125 crore in revenue at full utilization. But a strategy pivot that is not acknowledged is a concern for trust. Investors should demand a clear explanation of when the 3D printer actually launched and why the story changed.
Prevest Denpro's numbers are real, but its timeline on 3D printers isn't. That's a credibility gap that needs bridging.